Edgewise Therapeutics Schedules Annual Meeting, Seeks Director & Auditor Approval
Ticker: EWTX · Form: 8-K · Filed: Apr 2, 2025 · CIK: 1710072
| Field | Detail |
|---|---|
| Company | Edgewise Therapeutics, Inc. (EWTX) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-meeting, governance, auditor
Related Tickers: EDWX
TL;DR
Edgewise Therapeutics (EDWX) holding annual meeting May 15th for director votes & auditor approval.
AI Summary
Edgewise Therapeutics, Inc. filed an 8-K on April 2, 2025, to report on an upcoming Annual Meeting of Stockholders scheduled for May 15, 2025. The company is seeking stockholder approval for the election of two Class II directors, Mr. David M. E. Brown and Ms. Sarah K. Gordon, to serve until the 2028 annual meeting. Additionally, stockholders will vote on the ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Why It Matters
This filing outlines key corporate governance decisions, including director elections and auditor ratification, which are crucial for investor confidence and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine corporate filing regarding an annual meeting and does not involve significant financial or operational changes.
Key Players & Entities
- Edgewise Therapeutics, Inc. (company) — Registrant
- David M. E. Brown (person) — Nominee for Class II Director
- Sarah K. Gordon (person) — Nominee for Class II Director
- PricewaterhouseCoopers LLP (company) — Proposed Independent Registered Public Accounting Firm
- May 15, 2025 (date) — Date of Annual Meeting of Stockholders
- April 2, 2025 (date) — Date of Report
- 2028 (date) — Term end for elected directors
- December 31, 2025 (date) — Fiscal year end for auditor ratification
FAQ
When is the Edgewise Therapeutics Annual Meeting of Stockholders?
The Annual Meeting of Stockholders is scheduled for May 15, 2025.
Who are the proposed Class II directors for election?
The proposed Class II directors are Mr. David M. E. Brown and Ms. Sarah K. Gordon.
Until when will the elected Class II directors serve?
The elected Class II directors will serve until the 2028 annual meeting of stockholders.
What is the purpose of ratifying PricewaterhouseCoopers LLP?
Stockholders are being asked to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
What is the company's principal executive office location?
The company's principal executive offices are located at 1715 38th St., Boulder, CO 80301.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 2, 2025 by David M. E. Brown regarding Edgewise Therapeutics, Inc. (EWTX).